Fixes in financing : financial innovations for translational research.
THE FINANCING GAP FOR TRANSLATIONAL RESEARCH is widening. Traditional investors in translational research—large- and medium-cap biopharmaceutical companies and life science-focused venture capital funds—are becoming increasingly risk adverse in the face of escalating challenges in the early stages o...
Saved in:
| Format: | Ebook |
|---|---|
| Language: | English |
| Published: |
[Place of publication not identified] :
Milken Institute,
2012.
|
| Subjects: | |
| Online Access: | Business Source Complete |
| Summary: | THE FINANCING GAP FOR TRANSLATIONAL RESEARCH is widening. Traditional investors in translational research—large- and medium-cap biopharmaceutical companies and life science-focused venture capital funds—are becoming increasingly risk adverse in the face of escalating challenges in the early stages of the drug development process. To counteract this trend, the medical research field needs to increase the field of promising research ventures that are also attractive investment opportunities by modifying both the research management process as well as current financing methods. The industry needs novel approaches to early-stage drug development that better manage risk, lower capital cost and improve research effectiveness, create diverse portfolios, leverage risk-tolerant capital, and access new capital sources. With these issues in mind, the Milken Institute and Faster Cures, the Milken Institute's Center for Accelerating Medical Solutions, hosted a Financial Innovations Lab TM on July 19, 2011, in New York City. The Lab was convened to address an industry-widegap in funding for drug development—the so-called Valley of Death." -- p. [2]. |
|---|---|
| Item Description: | "April 2012. A Financial Innovations Lab Report". |
| Physical Description: | 1 online resource (26 pages) : colour illustrations |